BYHEALTH CO., LTD |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 15.2 CNY | -0.98% |
|
-4.46% | -10.75% |
| Apr. 25 | Byhealth Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| Apr. 12 | Byhealth Co., Ltd Approves Cash Dividend for the Year 2023 | CI |
| Sales 2024 * | 10.2B 1.41B | Sales 2025 * | 11.4B 1.57B | Capitalization | 25.85B 3.57B |
|---|---|---|---|---|---|
| Net income 2024 * | 1.87B 258M | Net income 2025 * | 2.18B 301M | EV / Sales 2024 * | 2.33 x |
| Net cash position 2024 * | 2.07B 286M | Net cash position 2025 * | 2.14B 295M | EV / Sales 2025 * | 2.08 x |
| P/E ratio 2024 * |
13.8
x | P/E ratio 2025 * |
11.9
x | Employees | 3,745 |
| Yield 2024 * |
4.52% | Yield 2025 * |
4.68% | Free-Float | 25.61% |
More Fundamentals
* Assessed data
More news
| 1 day | -0.98% | ||
| 1 week | -4.46% | ||
| Current month | -4.04% | ||
| 1 month | -2.31% | ||
| 3 months | -9.04% | ||
| 6 months | -16.99% | ||
| Current year | -10.75% |
1 week
15.16
16.02
1 month
15.1616.15
Current year
14.1817.84
1 year
14.1824.58
3 years
14.1837.75
5 years
14.1737.90
10 years
10.3337.90
| Managers | Title | Age | Since |
|---|---|---|---|
Zhi Cheng Lin
CEO | Chief Executive Officer | 56 | 11-06-30 |
Bai Lin He
DFI | Director of Finance/CFO | - | 23-08-23 |
Zhuo Yi Wu
CHM | Chairman | 46 | 10-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Yun Chao Liang
CHM | Chairman | 55 | 08-09-15 |
Hui Tang
BRD | Director/Board Member | 56 | 08-09-15 |
Shui Sheng Liang
BRD | Director/Board Member | 59 | 11-09-25 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-24 | 15.2 | -0.98% | 7,453,600 |
| 24-05-23 | 15.35 | -2.48% | 11,231,300 |
| 24-05-22 | 15.74 | -0.76% | 6,862,900 |
| 24-05-21 | 15.86 | -0.13% | 7,852,576 |
| 24-05-20 | 15.88 | -0.19% | 9,834,264 |
End-of-day quote Shenzhen S.E., May 23, 2024
More quotes
By-health Co Ltd is a China-based company principally engaged in the research, development, production, and distribution of nutrition supplements. The Company's main products include protein powders, collagen protein, vitamin C tablets, vitamin B tablets, natural vitamin E capsules, vitamin A and D soft capsules, calcium and vitamin D soft capsules, bovine colostrum calcium tablets, bone collagen calcium tablets, spirulina tablets, grape seed tablets, wheat germ oil soft capsules, deep-sea fish oil soft capsules, tuna oil soft capsules, propolis soft capsules, soybean phospholipids soft capsules and squalene soft capsules, among others. The Company distributes products both in the domestic market and to overseas markets.
Sector
Food Processing
Calendar
2024-08-04
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
D
Sell
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
15.2
CNY
Average target price
22.19
CNY
Spread / Average Target
+46.00%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -10.75% | 3.57B | |
| +13.97% | 8.2B | |
| +5.29% | 7.61B | |
| +0.60% | 5.95B | |
| -6.04% | 3.72B | |
| -7.53% | 1.27B | |
| -29.55% | 1.07B | |
| +14.57% | 988M | |
| -12.85% | 890M | |
| -18.06% | 789M |
- Stock Market
- Equities
- 300146 Stock
